Isicom

Levodopa/Carbidopa, the active ingredient in Isicom, is a Levodopa/Carbidopa combination presented as an oral tablet for oral administration. It is indicated for the management of Parkinson's disease and Parkinsonian syndromes in adult patients, helping to restore central dopamine levels.

GNH USA supplies Isicom as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains, competitive pricing, and responsive technical support.

Isicom (levodopa/carbidopa) is used in the dopaminergic pathway to manage Parkinsonian disorders.

- Parkinson's disease: improves motor symptoms by increasing central dopamine levels. - Parkinsonian syndrome: alleviates rigidity, bradykinesia, and tremor. - Motor fluctuations in Parkinson's disease: reduces "off" periods and enhances functional mobility.

Adverse reactions may occur with levodopa/carbidopa therapy.

Common Side Effects: - Nausea - Vomiting - Orthostatic hypotension - Dizziness - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Severe hypotension or syncope - Psychiatric disturbances (hallucinations, confusion) - Cardiac arrhythmias - Neuroleptic malignant‑like syndrome

Levodopa/carbidopa requires careful monitoring to minimize risks.

- Monitor blood pressure: watch for orthostatic hypotension, especially after dose initiation. - Assess psychiatric status: observe for hallucinations, confusion, or mood changes. - Adjust dose in renal impairment: reduced clearance may increase exposure. - Avoid abrupt discontinuation: taper gradually to prevent withdrawal symptoms. - Use with caution in elderly patients: increased susceptibility to side effects. - Store at room temperature: keep in the original pack, protect from moisture and light.

Levodopa/carbidopa can interact with several medications.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Antipsychotics (e.g., haloperidol, risperidone): may block dopaminergic effects. - Antihypertensive agents: additive hypotensive effect.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors (e.g., selegiline): may enhance dopaminergic activity. - Iron or calcium supplements: can reduce levodopa absorption. - Carbonic anhydrase inhibitors (e.g., acetazolamide): may increase levodopa plasma levels.